A critical review of improvement rates for laser therapy used to treat toenail onychomycosis

被引:37
作者
Gupta, A. K. [1 ,2 ]
Versteeg, S. G. [2 ]
机构
[1] Univ Toronto, Dept Med, Sch Med, Toronto, ON, Canada
[2] Mediprobe Res Inc, London, ON, Canada
关键词
ALUMINUM-GARNET LASER; NDYAG LASER; CLINICAL-EFFICACY; ANTIFUNGAL AGENT; SAFETY; DERMATOPHYTES; TERBINAFINE; DIAGNOSIS; MODERATE; PATIENT;
D O I
10.1111/jdv.14212
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Onychomycosis is a nail infection that is primary caused by dermatophytes. Alternative treatments are needed as current therapies (oral and topical antifungals) have limited effectiveness. Lasers are currently approved by the FDA to temporarily increase the amount of clear nail in onychomycosis patients. Lasers can theoretically elicit fungicidal effects but in practice produce mixed results. This review compared laser-induced improvement rates to FDA-approved indications and traditional onychomycosis treatments. A review of the literature (PubMed, Clinicaltrials.gov, Medline and Embase) was used to locate articles for this review. RCTs, non-randomized, uncontrolled and retrospective studies that included at least one of the following measures were eligible; complete cure, mycological cure, clinical improvement and clinical cure. Mycological cure (negative culture and negative microscopy) was evaluated in two studies using patients as the unit of analysis with an average rate of 11%, increasing to 63% when nails were used as the unit of analysis (three studies). Clinical cure (100% clear nail) was evaluated in six studies with a rate of 13% using nails as the unit of analysis and 13% when patients were used as the unit of analysis (two studies). Clinical improvement (at any time point) was found in 36% of patients (five studies) and 67% of nails (nine studies). Nail clarity as measured by clear nail growth and/or nail plate/bed clearance at 12 weeks was found to be 2.6 mm across onychomycotic nails. Laser studies, to date, provide preliminary evidence of clinical improvement and clear nail growth in toenail onychomycosis, consistent with the FDA clearance for aesthetic endpoints. Laser studies however do not provide efficacy rates for medical endpoints that equate or exceed those found with traditional therapies (oral and topical treatments).
引用
收藏
页码:1111 / 1118
页数:8
相关论文
共 64 条
  • [1] Extended theory of selective photothermolysis
    Altshuler, GB
    Anderson, RR
    Manstein, D
    Zenzie, HH
    Smirnov, MZ
    [J]. LASERS IN SURGERY AND MEDICINE, 2001, 29 (05) : 416 - 432
  • [2] SELECTIVE PHOTOTHERMOLYSIS - PRECISE MICROSURGERY BY SELECTIVE ABSORPTION OF PULSED RADIATION
    ANDERSON, RR
    PARRISH, JA
    [J]. SCIENCE, 1983, 220 (4596) : 524 - 527
  • [3] [Anonymous], 2015, DESIGN TRI PROT V6 0
  • [4] Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis
    Bhatta, Anil Kumar
    Keyal, Uma
    Huang, Xin
    Zhao, Jing Jun
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 916 - 923
  • [5] Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser
    Carney, Caitlin
    Cantrell, Wendy
    Warner, Judy
    Elewski, Boni
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (04) : 578 - 582
  • [6] A New Classification System for Grading the Severity of Onychomycosis Onychomycosis Severity Index
    Carney, Caitlin
    Tosti, Antonella
    Daniel, Ralph
    Scher, Richard
    Rich, Phoebe
    DeCoster, Jamie
    Elewski, Boni
    [J]. ARCHIVES OF DERMATOLOGY, 2011, 147 (11) : 1277 - 1282
  • [7] Fungal Nail Disease
    de Berker, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) : 2108 - 2116
  • [8] The association of fractional CO2 laser 10.600nm and photodynamic therapy in the treatment of onychomycosis
    de Oliveira, Guilherme Bueno
    Antonio, Joao Roberto
    Antonio, Carlos Roberto
    Tome, Fernanda Alves
    [J]. ANAIS BRASILEIROS DE DERMATOLOGIA, 2015, 90 (04) : 468 - 471
  • [9] The effect of toenail onychomycosis on patient quality of life
    Elewski, BE
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (10) : 754 - 756
  • [10] Elewski BE, 2013, ANACOR PHARM